Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6. Read more about Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6.
Prostatic expression of hensin, a protein implicated in epithelial terminal differentiation. Read more about Prostatic expression of hensin, a protein implicated in epithelial terminal differentiation.
Cultured stromal cells: an in vitro model of prostatic mesenchymal biology. Read more about Cultured stromal cells: an in vitro model of prostatic mesenchymal biology.
Replication linkage study for prostate cancer susceptibility genes. Read more about Replication linkage study for prostate cancer susceptibility genes.
Efficacy and toxicity of radioimmunotherapy with (90)Y-DOTA-peptide-ChL6 for PC3-tumored mice. Read more about Efficacy and toxicity of radioimmunotherapy with (90)Y-DOTA-peptide-ChL6 for PC3-tumored mice.
Workgroup 2: human xenograft models of prostate cancer. Read more about Workgroup 2: human xenograft models of prostate cancer.
Basic FGF, EGF, and PDGF modify TGFbeta-induction of smooth muscle cell phenotype in human prostatic stromal cells. Read more about Basic FGF, EGF, and PDGF modify TGFbeta-induction of smooth muscle cell phenotype in human prostatic stromal cells.
Parathyroid hormone-related protein is not an autocrine growth factor for normal prostatic epithelial cells. Read more about Parathyroid hormone-related protein is not an autocrine growth factor for normal prostatic epithelial cells.
Parathyroid hormone--related protein (PTHrP) is an epidermal growth factor-regulated secretory product of human prostatic epithelial cells. Read more about Parathyroid hormone--related protein (PTHrP) is an epidermal growth factor-regulated secretory product of human prostatic epithelial cells.
Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki-67 and PCNA expression. Read more about Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki-67 and PCNA expression.
